{
    "clinical_study": {
        "@rank": "161500", 
        "arm_group": [
            {
                "arm_group_label": "Q-QIV PRIM", 
                "arm_group_type": "Experimental", 
                "description": "Healthy primed children receiving one Q-QIV study vaccine dose on Day 0."
            }, 
            {
                "arm_group_label": "Q-QIV UNPRIM", 
                "arm_group_type": "Experimental", 
                "description": "Healthy unprimed children receiving two Q-QIV study vaccine doses on Day 0 and Day 28."
            }, 
            {
                "arm_group_label": "TIV-YB PRIM", 
                "arm_group_type": "Active Comparator", 
                "description": "Healthy primed children receiving one dose of Fluzone\u00ae on Day 0."
            }, 
            {
                "arm_group_label": "TIV-YB UNPRIM", 
                "arm_group_type": "Active Comparator", 
                "description": "Healthy unprimed children receiving two doses of Fluzone\u00ae on Day 0 and Day 28."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the immunogenicity and safety of the new influenza\n      vaccine GSK2282512A (FLU Q-QIV) and compare its activity to Sanofi Pasteur's Fluzone\u00ae (TIV)\n      in children 6 to 35 months of age."
        }, 
        "brief_title": "Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "The subjects will be randomised (1:1) in the two treatment groups (Q-QIV and TIV-YB) to\n      explore response to vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion\n             of the investigator, can and will comply, with the requirements of the protocol.\n\n          -  A male or female between, and including, 6 and 35 months of age at the time of the\n             first vaccination.\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Subjects in stable health as determined by investigator's clinical examination and\n             assessment of subject's medical history.\n\n          -  Subjects are eligible regardless of history of administration of influenza vaccine in\n             a previous season.\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine, or planned use during the\n             study period. Routine registered childhood vaccinations are permitted.\n\n          -  Child in care.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs within\n             six months prior to the first vaccine dose. For corticosteroids, this will mean\n             prednisone \u2265 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.\n\n          -  Prior receipt of any seasonal or pandemic influenza vaccine within six months\n             preceding the first dose of study vaccine, or planned use during the study period.\n\n          -  Administration of immunoglobulins and/or any blood products within the three months\n             preceding the first dose of study vaccine or planned administration during the study\n             period.\n\n          -  History of Guillain-Barr\u00e9 syndrome within six weeks of receipt of prior influenza\n             vaccine.\n\n          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of\n             anaphylactic-type reaction to consumption of eggs; or a history of severe adverse\n             reaction to a previous influenza vaccine.\n\n          -  Acute disease and/or fever at the time of enrollment.\n\n               -  Fever is defined as temperature \u2265 38.0\u00b0C/100.4\u00b0F by any method.\n\n               -  Subjects with a minor illness without fever may be enrolled at the discretion of\n                  the investigator.\n\n          -  Any significant disorder of coagulation or treatment with warfarin derivatives or\n             heparin.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  Any other condition which, in the opinion of the investigator, prevents the subject\n             from participating in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Months", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "316", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974895", 
            "org_study_id": "200806"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Q-QIV UNPRIM", 
                    "Q-QIV PRIM"
                ], 
                "description": "1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects \u226512 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.", 
                "intervention_name": "FLU Q-QIV (GSK2282512A)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "TIV-YB PRIM", 
                    "TIV-YB UNPRIM"
                ], 
                "description": "1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects \u226512 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.", 
                "intervention_name": "Fluzone\u00ae", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Children", 
            "Immunogenicity", 
            "Fluzone\u00ae", 
            "6 to 35 months of age", 
            "Seasonal influenza", 
            "Safety"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95822"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Covina", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91790"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Altamonte Springs", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32701"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fall River", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02721"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woburn", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01801"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stevensville", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49127"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44121"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hermitage", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16148"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barnwell", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29812"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheraw", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29520"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76135"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) in Children 6 to 35 Months of Age", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Humoral immune response to each strain of FLU Q-QIV", 
                "safety_issue": "No", 
                "time_frame": "On Day 0"
            }, 
            {
                "measure": "Humoral immune response to each strain of FLU Q-QIV", 
                "safety_issue": "No", 
                "time_frame": "At 28 days after the last vaccine dose (Day 28 and Day 56 for primed and unprimed subjects respectively)"
            }
        ], 
        "removed_countries": {
            "country": "Mexico"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Humoral immune response against the B/Victoria strain", 
                "safety_issue": "No", 
                "time_frame": "28 days after the last vaccine"
            }, 
            {
                "measure": "Humoral immune response to each strain", 
                "safety_issue": "No", 
                "time_frame": "On Day 0 and 28 days after the last vaccine (Day 28 and Day 56 for primed and unprimed subjects respectively)"
            }, 
            {
                "measure": "Occurrence of solicited local and general AEs", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (i.e. day of vaccination and six subsequent days) after each vaccination"
            }, 
            {
                "measure": "Occurrence of unsolicited AEs", 
                "safety_issue": "No", 
                "time_frame": "During a 28-day follow-up period (i.e. day of vaccination and 27 subsequent days) after each vaccination"
            }, 
            {
                "measure": "Occurrence of Medically Attended Adverse Events (MAEs), Serious Adverse Events (SAEs) and Potential Immune-Mediated Diseases (pIMDs)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Day 0 to Day 180)"
            }, 
            {
                "measure": "Occurrence of any fever (\u2265 38\u00b0C) or Grade 3 or higher (> 39\u00b0C) fever", 
                "safety_issue": "No", 
                "time_frame": "During a 4-day follow-up period after Dose 1 (Day 0-3) or Dose 2 (Day 28-31)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}